TFA
SUPN icon

Transamerica Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Transamerica Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325 Hold
7
– – ﹤0.01% 1778
2026
Q1 		$361 Hold
7
– – ﹤0.01% 1540
2025
Q4 		$348 Sell
7
-11
-61% -$535 ﹤0.01% 1433
2025
Q3 		$860 Buy
+18
New +$725 ﹤0.01% 1195

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Transamerica Financial Advisors's SUPN Position: Q2 2026 in Review

Transamerica Financial Advisors held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 7 shares worth $325. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Transamerica Financial Advisors first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. The position peaked at $860 in Q3 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Transamerica Financial Advisors held 7 shares of Supernus Pharmaceuticals worth $325 as of Q2 2026.
  • Transamerica Financial Advisors left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1778 holding.
  • Transamerica Financial Advisors first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Transamerica Financial Advisors's Supernus Pharmaceuticals position peaked at $860 in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.